Companies conclude research and option phase of 2014 RNAi therapeutics alliance in rare genetic diseases, Sanofi says.
- Alliance produced “important” medicine treating ATTR amyloidosis; one molecule for treating hemophilia in clinical trials
- Collaboration for patisiran, vutrisiran (ALN-TTRsc02) and fitusiran continue unchanged
- Alnylam to continue work on additional investigational asset in undisclosed rare genetic disease through end of IND-enabling studies
- Sanofi will be responsible for any potential further development or commercialization of such asset
- Alnylam eligible to receive tiered double-digit royalties on global net sales if drug approved
©2019 Bloomberg L.P. All rights reserved. Used with permission
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.